IP Library › Granted Patent US 9,951,100
Granted Patent B2
US 9,951,100 · App. 14/676,727 · Granted Apr 24, 2018

Method for isolating and purifying recombinant human serum albumin from transgenic rice grain

Inventors: Daichang Yang (Hubei, CN); Yang He (Hubei, CN); Guangfei Li (Hubei, CN); Jingru Liu (Hubei, CN)
Assignee: HEALTHGEN BIOTECHNOLOGY CO., LTD.
C07K1/18B01J20/3285C07K14/765
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,951,100
App. No.
14/676,727
Granted
Apr 24, 2018
Kind
B2
Abstract

A method for separating and purifying recombinant human serum albumin (rHSA) from transgenic rice grain, sequentially comprising the steps of: 1) subjecting crude extract of rHSA to cation exchange chromatography to obtain primary product I; 2) subjecting the primary product I to anion exchange chromatography to obtain secondary product II; 3) subjecting the secondary product II to hydrophobic chromatography to obtain purified rHSA. The method may further comprise a step of ceramic hydroxyapatite chromatography prior to the hydrophobic chromatography. The method has the advantages of low cost and easy operation. The resultant rHSA has a purity of about 99% by HPLC.

Claims (30)

1. A method for isolating and purifying recombinant human serum albumin (rHSA) from transgenic rice grain, sequentially comprising the steps of:

1) subjecting a crude extract from the transgenic rice grain containing the recombinant human serum albumin to cation exchange chromatography to obtain primary product I;

2) subjecting the primary product I to anion exchange chromatography to obtain secondary product II that contains the recombinant human serum albumin, wherein the secondary product II further comprises ammonium sulfate at a concentration from about 0.1 M to about 1 M;

3) subjecting the secondary product II to hydrophobic chromatography, under a condition that the rHSA does not adsorb to the resins of the hydrophobic chromatography; and

4) recovering non-adsorbed flow-through fractions from the hydrophobic chromatography to obtain the purified recombinant human serum albumin having a purity of more than about 99% rHSA monomer plus dimer and polymer by HPLC.

2. The method according to claim 1 , further comprising a step of subjecting the secondary product II to ceramic hydroxyapatite chromatography prior to the hydrophobic chromatography of step 3).

3. The method according to claim 2 , wherein the ceramic hydroxyapatite chromatography is performed on a chromatography media selected from Macro-prep Ceramic hydroxyapatite Type I and Type II media.

4. The method according to claim 3 , wherein the ceramic hydroxyapatite chromatography employs an elution buffer comprising a phosphate buffer with a pH of 7.0-7.5.

5. The method according to claim 2 , wherein the purified recombinant human serum albumin has a purity of about 99% rHSA monomer by HPLC.

6. The method according to claim 1 , wherein the cation exchange chromatography is performed on a chromatography media selected from the group consisting of UNOsphere S, Capto MMC, Nuvia S and MacroPrep-CM.

7. The method according to claim 6 , wherein the cation exchange chromatography is performed on UNOsphere S or Capto MMC.

8. The method according to claim 6 , wherein the cation exchange chromatography is performed on UNOsphere S and employs an elution buffer comprising acetate buffer, 0.25 M sodium chloride, with a pH of 5.2.

9. The method according to claim 6 , wherein the cation exchange chromatography is performed on Nuvia S and employs an elution buffer comprising acetate buffer, 0.25 M sodium chloride, with a pH of 5.0.

10. The method according to claim 6 , wherein the cation exchange chromatography is performed on Capto MMC, and employs a washing buffer comprising acetate buffer, 1 M sodium chloride, with a pH of 4.7 to remove non-target proteins, and an elution buffer comprising acetate buffer, 1 M sodium chloride, with a pH of 6.7 to elute the recombinant human serum albumin.

11. The method according to claim 6 , wherein the cation exchange chromatography is performed on MacroPrep-CM, and employs a washing buffer comprising acetate buffer, 1 M sodium chloride, with a pH of 4.7 to remove non-target proteins, and an elution buffer comprising acetate buffer, 1 M sodium chloride, with a pH of 6.5 to elute the recombinant human serum albumin.

12. The method according to claim 1 , wherein the anion exchange chromatography is performed on a chromatography media selected from the group consisting of Q Sepharose FF, UNOsphere Q and DEAE Sepharose FF.

13. The method according to claim 12 , wherein the anion exchange chromatography is performed on Q Sepharose FF.

14. The method according to claim 12 , wherein the anion exchange chromatography is performed on Q Sepharose FF and employs an elution buffer comprising a phosphate buffer, 0.25 M sodium chloride, with a pH of 6.0-7.0.

15. The method according to claim 12 , wherein the anion exchange chromatography is performed on DEAE Sepharose FF, and employs a washing buffer comprising phosphate buffer, 0.1 M sodium chloride with a pH of 6.0-7.0 to remove non-target proteins, and an elution buffer comprising a phosphate buffer, 0.25 M sodium chloride, with a pH of 6.0-7.0 to elute the recombinant human serum albumin.

16. The method according to claim 1 , wherein the hydrophobic chromatography is performed on a chromatography media selected from the group consisting of Phenyl Sepharose HP, Phenyl Sepharose FF, macro-prep t-butyl and macro-prep methyl.

17. The method according to claim 16 , wherein the hydrophobic chromatography is performed on Phenyl Sepharose HP.

18. The method according to claim 16 , wherein the hydrophobic chromatography is performed on Phenyl Sepharose HP, and the secondary product II is adjusted to 0.4 M ammonium sulfate prior to the hydrophobic chromatography step.

19. The method according to claim 16 , wherein the hydrophobic chromatography is performed on Phenyl Sepharose FF, and the secondary product II is adjusted to 0.1 M ammonium sulfate prior to the hydrophobic chromatography step.

20. The method according to claim 16 , wherein the hydrophobic chromatography is performed on MacroPrep-t-Butyl, and the secondary product II is adjusted to 0.6-1.0 M ammonium sulfate prior to the hydrophobic chromatography step.

21. The method according to claim 1 , wherein said crude extract of the recombinant human serum albumin is prepared by a method comprising the steps of:

i) mixing milled transgenic rice grain containing the recombinant human serum albumin with an extraction buffer in a w/v (kg/L) ratio of 1:5 and extracting at 55-60° C. for 1-1.5 hours to obtain mixture I; said extraction buffer comprising 10-30 mM phosphate buffer, 10-20 mM sodium acetate, 15-30 mM ammonium sulfate and 5-20 mM sodium caprylate, with a pH of 6.5-8;

ii) adjusting the pH of mixture I of step i) to 4.0-4.5 and precipitating it for 3-12 hours to obtain mixture II;

iii) filtrating the mixture II of step ii) and collecting the filtrate to obtain a crude extract containing high concentration of recombinant human serum albumin; said filtrating comprising steps of filtrating by pressure filtration with a filter cloth type plate-frame filter, then filtrating by micro-filtration with a polyethersulfone hollow fiber membrane with a pore size of 0.20 μm-0.45 μm.

22. The method according to claim 1 , wherein the cation exchange chromatography employs a loading buffer comprising an acetate buffer with a pH less than 5.0.

23. The method according to claim 1 , wherein the cation exchange chromatography employs an elution buffer comprising an acetate buffer and sodium chloride, or a phosphate buffer and sodium chloride; with a pH of 5.0-6.7.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2015
From: YANG, DAICHANG; HE, YANG; LI, GUANGFEI; LIU, JINGRU
To: HEALTHGEN BIOTECHNOLOGY CO., LTD.
Reel/Frame 035782/0871 →
Priority Claims (1)
CN 2010 1 0606635 · Dec 24, 2010 · national
Continuity (2)
Continuation 13206884 · Aug 10, 2011
Related Publication 20150203530A1 · Jul 23, 2015